EchoSolv AS vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

EchoSolv AS

by Echo IQ

EchoNext

by Pathway Labs

AI Verdict

EchoSolv AS and EchoNext are adjacent tools in cardiology AI, both offering FDA-cleared clinical decision support. EchoSolv AS specifically focuses on identifying severe aortic stenosis risk from echocardiogram measurements, while EchoNext provides broader detection of hidden structural heart disease, including heart failure and valve disease, using standard ECGs. The choice between them depends on the specific diagnostic need: detailed aortic stenosis risk assessment versus general structural heart disease screening.

Choose EchoSolv AS if…

Choose EchoSolv AS if your cardiology department needs an AI-powered clinical decision support tool to specifically enhance the accuracy and efficiency of severe aortic stenosis (sAS) diagnosis from echocardiograms. It's ideal for providing a 'second reader' to prioritize studies for closer review and ensuring consistent assessment based on measurements, integrating seamlessly into existing PACS workflows without EMR integration.

View EchoSolv AS →

Choose EchoNext if…

Choose EchoNext if your practice or hospital aims to broadly screen for hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, using standard ECGs. This tool is best suited for early detection in a wide patient population, potentially identifying at-risk individuals who would benefit from further echocardiographic evaluation, and can be deployed through the OpenEvidence platform.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	EchoSolv AS	EchoNext
Pricing	Unknown	Starts at $600/month
Deployment	Cloud-based	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

EchoSolv AS

EchoSolv AS is designed to integrate seamlessly into existing clinical workflows and PACS systems without requiring EMR integration, which generally simplifies deployment and reduces friction for users. It also boasts ultra-fast risk detection (under 3 seconds) and analyzes numerical measurements rather than images, potentially streamlining the review process.

Clinical Value

EchoNext

While both tools are FDA-cleared and clinically validated, EchoNext demonstrates broader clinical utility by detecting a wider range of structural heart diseases (heart failure, valve disease, pulmonary hypertension, severe hypertrophy) from a standard ECG, a more widely available and less expensive test than an echocardiogram. EchoNext has also shown higher accuracy than cardiologists in identifying structural heart problems.

Pricing & Value

EchoNext

EchoNext provides transparent tiered pricing starting at $600/month, including details on implementation fees and annual discounts. EchoSolv AS's pricing is not publicly disclosed, making it difficult to assess its value proposition directly, although it operates on a subscription-based model with a fee-per-use reimbursement pathway.

Enterprise Readiness

EchoSolv AS

EchoSolv AS has a clear focus on integration into existing PACS systems without EMR integration, which simplifies enterprise deployment. It also has established reimbursement pathways with a miscellaneous code and an anticipated Category III CPT code, indicating a more mature commercialization strategy for large-scale adoption.

Innovation

EchoNext

EchoNext stands out for its innovative approach of detecting a broad spectrum of hidden structural heart diseases from a standard ECG, a readily available and inexpensive test. This has the potential to create a new screening paradigm and improve early detection in settings where echocardiography access is limited.

Support & Docs

Tie

Neither tool provides specific details on their support and documentation offerings in the provided information or web searches. Both are FDA-cleared, implying a certain level of documentation, but direct comparisons of support resources are not possible.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	EchoSolv AS	EchoNext
Tool Name	EchoSolv AS	EchoNext
Company	Echo IQ	Pathway Labs
Description	EchoSolv AS is an FDA-cleared, AI-powered clinical decision support platform by Echo IQ that analyzes echocardiograms to identify patients at risk for severe aortic stenosis with high accuracy and efficiency, integrating into existing workflows.	EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Primary Analysis Input	Echocardiograms (numerical measurements, not images)	Standard 12-lead ECGs
Key Detections/Identifications	High-probability severe aortic stenosis (sAS) patients	Hidden structural heart disease, heart failure risk, valve disease, pulmonary hypertension indicators

Videos

Demos, reviews, and walkthroughs featuring EchoSolv AS and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

EchoSolv AS is designed to fit into existing echocardiography workflows and integrates with PACS systems, without requiring EMR integration. EchoNext, on the other hand, integrates with the OpenEvidence clinical decision support platform, which aims to embed its screening output directly into tools many physicians already use during patient visits, avoiding a separate workflow or system.

What is the accuracy and sensitivity of each tool in detecting cardiac conditions?

EchoSolv AS has demonstrated high accuracy in detecting severe aortic stenosis, with an AUC of 0.986, 82.2% sensitivity, and 98.1% specificity in one study. EchoNext has shown high accuracy in detecting structural heart disease from ECGs, with an AUROC of 85.2% in internal tests and 78-80% in external validation. In a comparison, EchoNext achieved 77% accuracy in identifying structural heart problems from ECGs, compared to 64% for cardiologists alone.

Which specific cardiac specialties are these tools best suited for, and what conditions do they primarily address?

EchoSolv AS is specifically designed for cardiology and cardiothoracic surgery, focusing on identifying patients at risk for severe aortic stenosis. EchoNext is suitable for a broader range of specialties including cardiology, family medicine, hospital medicine, and internal medicine, as it analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, severe hypertrophy, and pulmonary hypertension.

What is the learning curve for physicians to effectively use each tool?

EchoSolv AS is designed for real-world readiness and aims for faster clinical review using standardized, measurement-based AI and guideline analysis, suggesting a focus on ease of use within existing echocardiography interpretation practices. EchoNext is presented as a screening tool that uses standard 12-lead ECGs, which are routine tests, implying that the learning curve for inputting data may be minimal, with the AI providing the complex analysis.

What kind of customer support and training can be expected for each tool?

While specific details on support quality are not provided for either tool, Echo IQ is expanding commercial implementation and partnerships, suggesting a growing support infrastructure for EchoSolv AS. Pathway Labs, with EchoNext, has raised funding to expand into more health systems and integrate with OpenEvidence, which serves a large number of physicians, indicating a focus on broad accessibility and likely accompanying support for integration and use.

How quickly can a practice expect to see value from implementing these tools?

EchoSolv AS offers ultra-fast risk detection (under 3 seconds) and aims to reduce review time by 24.1%, suggesting a rapid time-to-value by improving efficiency in identifying severe aortic stenosis. EchoNext aims to enable earlier detection of structural heart disease, potentially reducing diagnostic delays and the burden of these conditions, which could translate to value through improved patient outcomes and more efficient resource allocation.

Do these tools offer audit-trail features for tracking usage and decisions?

EchoSolv AS includes comprehensive audit trails with role-based access controls, which can help track usage and ensure accountability. The provided information for EchoNext does not explicitly mention audit-trail features, but generally, robust clinical decision support platforms often incorporate such functionalities for compliance and oversight.